

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive recurrent ovarian cancer: A meta-analysis

Journal:	Cancer
Manuscript ID	CNCR-21-0218.R1
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Lee, Chee; University of Sydney, NHMRC Clinical Trials Centre Friedlander, Michael; Royal Hospital for Women and Nelune Cancer Centre, Department of Medical Oncology Tjokrowidjaja, Angelina Ledermann, Jonathan; UCL Cancer Institute, CR-UK and UCL Cancer Trilas Coleman, Robert Mirza, Mansoor; Rigshospitalet Matulonis, Ursula; Dana-Farber Cancer Institute, Department of Medical Oncology Pujade-Lauraine, Eric; AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Unité Cancer de la Femme et Recherche Clinique Bloomfield, Ralph Goble, Sandra Wang, Ping Glasspool, Rosalind Scott, Clare; Walter and Eliza Hall Institute of Medical Research, Stem Cells and Cancer
Keywords:	platinum sensitive recurrent ovarian cancer, BRCA mutation, homologous recombination deficiency, polyADP-ribose polymerase inhibitors, meta- analysis



Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive recurrent ovarian cancer: A meta-analysis

Running Title: Predicting benefit with PARP inhibitor

Word count: Abstract, 249 words; Manuscript, 3009 words.

Authors:

Chee Khoon Lee¹,PhD, Michael L Friedlander², PhD, Angelina Tjokrowidjaja¹, MPH, Jonathan A Ledermann³, MD, Robert L Coleman⁴, MD, Mansoor R Mirza⁵, MD, Ursula A. Matulonis⁶,MD, Eric Pujade-Lauraine⁷, PhD, Ralph Bloomfield⁸, MSc, Sandra Goble⁹, MS, Ping Wang¹⁰, PhD, Rosalind M. Glasspool¹¹, PhD, Clare L Scott¹², PhD, on behalf of the Gynecologic Cancer InterGroup Meta-analysis Committee

Affiliations:

¹National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia and the Australia New Zealand Gynaecological Oncology Group

²University of New South Wales Clinical School, Prince of Wales Hospital, Sydney, Australia and the Australia New Zealand Gynaecological Oncology Group

³UCL Cancer Institute and University College London Hospitals, London, UK

⁴Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
⁵Rigshospitalet–Copenhagen University Hospital, Copenhagen, Denmark and Nordic Society of Gynecological Oncology
⁶Dana–Farber Cancer Institute, Boston, Massachusetts, USA
⁷Université Paris Descartes, AP-HP, Paris, France and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
⁸Astrazeneca, Cambridge, UK
⁹Clovis Oncology, Boulder, Colorado, USA
¹⁰GlaxoSmithKline, Waltham, Massachusetts, USA

¹¹Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde and University of Glasgow, Glasgow, United Kingdom and Scottish Gynaecological Cancer Trials Group

¹²Walter and Eliza Hall Institute of Medical Research, University of Melbourne,Melbourne, Australia and the Australia New Zealand Gynaecological Oncology Group

Corresponding Author:

A/Prof Chee Khoon Lee, MBBS(Hons), FRACP, PhD NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia Email: chee.lee@ctc.usyd.edu.au Ph No: +61295625365; Fax No: +61295651863

Cancer

Funding: There is no specific funding received for this work

Conflict of Interest:

CKL, MF, JAL, MRM, EPL and RMG have received honoraria from AstraZeneca. CKL, MF, JAL, RLC and EPL has provided a consulting or advisory role to AstraZeneca. MF has been involved in a Speaker's bureau for AstraZeneca. CKL, MF, AT, RLC, UAM, EPL have received travel and accommodation funding from AstraZeneca. CKL and RLC have received research funding from AstraZeneca; MF, AT, JAL and MRM have received study grants (to institution) from AstraZeneca. JAL, MRM and RMG have received honoraria from Clovis Oncology. RLC and EPL have provided a consulting or advisory role to Clovis Oncology. JAL has been involved in a Speakers' bureau for Clovis Oncology. JAL and RLC has received travel and accommodation funding from Clovis Oncology. RLC has received research funding from Clovis Oncology, MRM has received study grants (to institution) from Clovis Oncology. MRM and EPL have received honoraria from GlaxoSmithKline. JAL has been involved in a Speakers' bureau for GlaxoSmithKline. RB discloses employment and Stockholder interests with AstraZeneca. SG discloses employment and Stockholder interests with Clovis Oncology. PW discloses employment and Stockholder interests with GlaxoSmithKline. CLS discloses non-financial support and/or other support from AstraZeneca and Clovis Oncology. EPL discloses other relationship with ARCAGY RESEARCH.

Authors contribution:

Conception and design: CKL, MF, CS Collection and assembly of data: CKL, AT, RB, SG, PW Data analysis and interpretation: All authors Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

Acknowledgement:

The authors acknowledge provision of unpublished subgroup data from AstraZeneca, Clovis Oncology, and GlaxoSmithKline

Cancer

Precis:

BRCA mutation status could predict for the magnitude of PARP inhibitor benefit in platinum-sensitive recurrent high grade ovarian tumor. However, absence of a BRCA mutation or homologous recombinant deficiency in high grade ovarian tumor could not be used to exclude patients from such therapy.

Abstract

Cancer

Background: We performed a meta-analysis to better quantify benefit of maintenance PARP inhibitor (PARPi) to inform practice in platinum-sensitive recurrent high grade ovarian cancer (PSROC) for these patient subsets: germline *BRCA* mutation (*gBRCAm*), somatic *BRCA* mutation (*sBRCAm*), wild-type *BRCA* and homologous recombinant deficient (HRD), homologous recombinant proficient (HRP), and baseline clinical prognostic characteristics.

Methods: Randomized trials comparing a PARPi versus placebo as maintenance treatment were identified from electronic databases. Treatment estimates for progression-free survival (PFS) were pooled across trials using the inverse variance weighted method.

Results: Four trials included 972 patients receiving a PARPi (olaparib, 31%; niraparib, 35%; or rucaparib, 34%), and 530 patients receiving placebo. For *gBRCAm1* (N=471), HR=0.29 (95% CI 0.23–0.37). For *gBRCAm2* (N=236), HR=0.26 (95% CI 0.17–0.39). For *sBRCAm* (N=123), HR=0.22 (95% CI 0.12–0.41). The treatment effect was similar between *gBRCAm* and *sBRCAm* (P=.48). In wild-type *BRCA* HRD tumors (excluding *sBRCAm*, N=309) HR=0.41 (95% CI 0.31–0.56). In wild-type *BRCA* HRP tumors (N=346), HR=0.64 (95% CI 0.49–0.83). The relative treatment effect was greater for *BRCAm* versus HRD (P=.03), *BRCAm* versus HRP (P<.00001), and HRD versus HRP subgroups (P<.00001) respectively. There was no difference in benefit based on age, response after recent chemotherapy, and prior bevacizumab.

Conclusions: In PSROC, maintenance PARPi improves PFS for all patient subsets. PARPi has similar magnitude of benefit for *sBRCAm* and *gBRCAm*. Although patients

with *BRCAm* derive the greatest benefit, the absence of a *BRCAm* or HRD could not be used to exclude patients from maintenance PARPi therapy.

Keywords: platinum sensitive recurrent ovarian cancer, BRCA mutation, homologous recombination deficiency, polyADP-ribose polymerase inhibitors, meta-analysis

Total number:

(1) text pages: 24

- (2) tables: 1
- (3) figures: 3
- (4) Supporting files for publication: 1

Cancer

Introduction

Cancers of the ovary, fallopian tube and peritoneum remain the most important causes of cancer deaths for women in developed countries¹. At diagnosis, the majority of women have advanced stage disease and approximately 80% will recur following surgery and chemotherapy. Women with platinum-sensitive recurrent ovarian cancer (PSROC), defined as relapse \geq 6 months after the most recent platinum-based chemotherapy, are usually re-treated with further platinum-based agents. There is usually a declining likelihood of response and shorter duration of benefit with each successive line of treatment. Multiple treatment strategies have been extensively investigated in PSROC with the aim of prolonging progression-free survival (PFS) and overall survival (OS). To date the most successful strategies are concomitant chemotherapy and bevacizumab followed by maintenance bevacizumab, and maintenance poly(ADP ribose) polymerase inhibitors (PARPi).

High-grade ovarian tumors accounts for the majority of PSROC and up to 50% are deficient in homologous recombination which is a key pathway involved in DNA damage repair²⁻⁶ and are therefore reliant on more error prone DNA repair pathways such as non-homologous end joining⁷. Various homologous recombination deficiencies have been recognized, including germline mutations of the *BRCA1/2* genes (*gBRCAm 1/2*), somatically acquired *BRCA* mutations (*sBRCAm*), epigenetic *BRCA1* inactivation, or other *BRCA*-independent pathways. To date, *sBRCAm1* were reported in 5–9% of sporadic ovarian tumors, whereas *sBRCAm2* were identified in 3–4% of cases⁸⁻¹⁰. *BRCAm* of either germline^{11, 12} or somatic mutations¹³ occurs more frequently in platinum sensitive than resistant tumors.

PARPi induce synthetic lethality in tumors with homologous recombination deficiency. Multiple randomized controlled trials (RCTs) in PSROC have reported that maintenance PARPi following response to platinum based chemotherapy significantly improves PFS and delays time to subsequent chemotherapy which has changed the standard of care¹³⁻¹⁷ and this treatment is gradually being introduced worldwide. The SOLO2 trial also reported an OS improvement with maintenance olaparib, with 28.3% of *gBRCAm* patients alive at 60 months without need for subsequent treatment, as compared with 12.8% in the placebo arm¹⁸. There is ongoing interest to determine which patient subgroups, beyond those with a *gBRCAm*, will benefit from maintenance PARPi and whether it is possible to use clinico-pathologic factors to select for these patients. This information will be clinically relevant, can help inform the design and interpretation of future trials, and can aid economic analyses.

This paper reports a meta-analysis of four RCTs using published and unpublished data of patient subsets to quantify the relative treatment benefit of maintenance PARPi over placebo in women with PSROC who have responded to platinum-based chemotherapy. We also aimed to determine the variation in treatment benefit based on patient, disease, and past treatment characteristics. This metaanalysis is valuable as individual RCTs were neither designed nor adequately powered to detect differences in treatment effect in these subgroups.

Methods

Study eligibility and identification

We included RCTs of recurrent PSROC with high-grade tumors if they compared PARPi as maintenance therapy versus placebo. Eligible RCTs were identified from

Cancer

MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Search terms used included "*BRCA*", "*BRCA*1", "*BRCA*2", "*BRCA*1 protein", "*BRCA*2 protein", "ovarian neoplasms", "platinum-sensitive", "poly(ADP Ribose) polymerase inhibitors" and "clinical trial". We retrieved relevant articles published between 2005 and 2019 with no language restrictions. Individual trial investigators were also contacted for unpublished subgroup data.

Data collection and analysis

For each RCT, we extracted the trial name, patients' clinico-pathologic characteristics and types of PARPi. Regardless of the primary endpoints of the included RCTs, this meta-analysis assessed treatment benefit based on PFS as assessed by local investigators (INV) as the primary outcome. We performed a sensitivity analysis to determine the consistency of the results based on blinded independent central review (BICR) PFS for all RCTs. BICR PFS was a pre-specified primary endpoint of one included RCT¹³.

We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for PFS based on homologous recombination repair (HRR) deficiency status: *gBRCAm*, *sBRCAm*, wild-type *BRCA* (*wtBRCA*) but homologous recombination deficient (HRD, excluding those with *sBRCAm*) and *wtBRCA* but homologous recombination proficient (HRP). Tumors with oncogenic germline and somatic mutations were classified as *BRCAm* and variants of unknown significance were classified as *wtBRCA*. If *BRCAm* was detected but the tumor was also tested to be HRP, these patients were classified based on their *BRCAm* status. HRD was defined differently in different RCTs. In one study¹⁶, tumors were classified as HRD if they had high genomic loss of heterozygosity

(LOH) as detected using Foundation Medicine T5 NGS assay (cutoff of 16% or greater). Other studies^{13, 19} defined HRD based on high LOH, telomeric allelic imbalance, and/or large-scale state transitions as detected using Myriad Genetics myChoice test (Genomic Instability Score of 42 or greater).

We also retrieved data on treatment effect for these clinicopathologic subgroups: age (<65 versus \geq 65 years), platinum-free interval (6–12 versus >12 months), response after most recent chemotherapy (complete response versus partial response), number of previous lines of platinum chemotherapy (2 versus >2) and use of bevacizumab treatment in conjunction with last platinum regimen (yes versus no).

Two of the authors (CKL, AT) extracted the data independently, and discrepancies were resolved by a third author (CLS). The risk of bias was assessed based on methods of randomization, allocation concealment, outcome assessments, attrition and reporting of the data. We reported our data based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines²⁰.

Statistical analysis

Pooled PFS HRs and 95% CIs were computed by using the inverse variance weighted method with fixed-effects models. Differences between subgroups were tested using methods described by Borenstein et al²¹. We used the χ^2 Cochran Q test to detect any heterogeneity across trials. We also evaluated publication bias by examining the funnel plot of the effect size for each RCT against the reciprocal of its standard error. The nominal level of significance was set at 5%.

Results

Page 11 of 58

Cancer

We identified four eligible RCTs^{13-17, 19} (Figure 1). Of 1677 patients who were randomly assigned to a PARPi or placebo, we analyzed only patient data from 1502 (89.6%). A total of 175 patients (ARIEL3¹⁶, N=59; Study 19 trial^{14, 15, 19}, N=62; NOVA trial¹³, N=54) were excluded because HRR deficiency status were unknown. All trials recruited patients with high-grade cancers of the ovary, fallopian tube and peritoneum. The majority had predominantly serous histology, whilst only the ARIEL3¹⁶ and SOLO2¹⁷ trials enrolled patients with endometriod and other rare histologies (N=28, 5%, and N=25, 8%, respectively). Table 1 outlines the demographic and treatment characteristics. All included studies were evaluated as low risk for bias (details not shown).

All study sponsors provided unpublished summary subgroup data. All RCTs had a double-blind, placebo-controlled design. The primary endpoint was PFS by BICR for the NOVA trial¹³; PFS by INV was the primary endpoint for other RCTs. The Study 19 trial^{14, 15, 19} was the only trial with a randomized phase II design and the HRR gene status of the tumor was determined retrospectively.

The SOLO2 trial¹⁷ recruited only *gBRCA*m carriers, whereas the remaining RCTs included *gBRCAm*, *sBRCAm* and *wtBRCA* patients. In the ARIEL3 trial¹⁶, *wtBRCA* tumors with HRD was defined based on high genomic LOH. In the Study 19 and NOVA trials, *wtBRCA* tumors with HRD were those with high LOH, telomeric allelic imbalance, and large-scale state transitions.

Benefit of PARP inhibitor in subgroups according to homologous recombination repair deficiency status

Across the trials, 972 patients received a PARPi (olaparib, N=301 [31%];

niraparib, N=336 [35%]; or rucaparib, N=335 [34%]), and 530 patients received placebo.

Among the 471 *gBRCAm1* patients, the pooled PFS HR was 0.29 (95% CI 0.23– 0.37, *P*<.00001; Figure 2). Among the 236 *gBRCAm2* patients, the pooled PFS HR was 0.26 (95% CI 0.17–0.39, *P*<.00001). In the 123 *sBRCA*m patients, the pooled PFS HR was 0.22 (95% CI 0.12–0.41, *P*<.00001).

The pooled PFS HR for both *gBRCAm1* and *gBRCAm2* only was 0.28 (95% CI 0.23–0.35, *P*<.00001). The pooled PFS HR for *gBRCAm1*, *gBRCAm2* and *sBRCAm* was 0.27 (95% CI 0.23–0.34, *P*<.00001).

The relative treatment effect was similar between gBRCAm1 and gBRCAm2 (P=.63). There was also no significant difference in treatment effect between gBRCAm1/2 and sBRCAm (P=.48).

There were 309 *wtBRCA* patients with HRD tumor (excluding s*BRCAm*). The pooled PFS HR was 0.41 (95% CI 0.31–0.56, *P*<.00001). In the 346 *wtBRCA* patients with HRP tumor, the pooled PFS HR was 0.64 (95% CI 0.49–0.83, *P*=.0006). The relative treatment effect was significantly greater for HRD than HRP subgroups (*P*<.00001).

The relative treatment effect was also significantly greater for *BRCAm* (both germline and somatic) than HRD subgroups (HR 0.27 versus 0.41, P=.03). A similar finding was observed for the comparison of *BRCAm* (both germline and somatic) with HRP subgroups (HR 0.27 versus 0.64, *P*<.00001).

Subgroup analyses by clinico-pathologic characteristics

 Cancer

Subgroup outcome data were available for age, response after most recent chemotherapy, number of previous lines of platinum chemotherapy and prior bevacizumab treatment.

In the *gBRCAm* cohort, the pooled HR for patients with only two prior platinum chemotherapy lines (N=420, 58%) was 0.31 (95% CI 0.24–0.41, *P*<.00001). Among the 302 (42%) patients who had more than two prior platinum chemotherapy lines, the pooled HR was 0.20 (95% CI 0.14–0.28, *P*<.00001). The relative treatment effect was borderline significant between these subgroups (*P*=.04; Figure 3). In this *gBRCAm* cohort, the relative treatment benefit of PARPi versus placebo did not vary substantially between the subgroups, based on age, response after most recent chemotherapy, and prior bevacizumab treatment (Figure 3).

In patients with HRD tumors but without s*BRCAm*, PFS HRs did not vary substantially between the subgroups defined by clinico-pathologic characteristics. For patients with HRP tumors, PFS HRs also did not vary substantially in these clinico-pathologic subgroups (Figure 3).

Impact of platinum-free interval on progression-free survival across patient cohorts

Platinum-free interval (PFI) was a stratification factor and defined consistently across all RCTs. A total of 834 patients had PFI greater than twelve months and 545 patients had PFI between six to twelve months. PFS HRs did not vary substantially according to PFI within the *gBRCAm*, HRD, and HRP subgroups (Figure 3).

However, amongst those with PFI greater than twelve months, the pooled PFS HR was 0.29 (95% CI 0.22–0.38, *P*<.00001) in 429 (51%) *gBRCAm* patients. In the 192

(23%) patients with HRD tumor (excluding s*BRCAm*), the pooled PFS HR was 0.34 (95% CI 0.23–0.50, *P*<.00001). There was no significant difference in treatment effect between *gBRCAm* and HRD subgroups (*P*=.56). In contrast, the pooled PFS HR was 0.67 (95% CI 0.48–0.92, *P*=.01) in 213 (26%) patients with HRP tumors. The treatment effect was significantly greater for the comparisons of *gBRCAm* versus HRP (*P*=.0001), and HRD versus HRP subgroups (*P*=.009).

Amongst those with PFI between six to twelve months, 295 (54%) *gBRCAm* patients had a pooled PFS HR of 0.25 (95% CI 0.19–0.34, *P*<.00001). In the 117 (22%) patients with HRD tumors, the pooled PFS HR was 0.54 (95% CI 0.34–0.87, *P*=.01). Among the 133 (24%) patients with HRP tumor, the pooled PFS HR was 0.59 (95% CI 0.38–0.90, *P*=.02). The treatment effect was significantly greater for *gBRCAm* than HRD subgroups (*P*=.007), and for *gBRCAm* than HRP subgroups (*P*=.001). There was no significant difference in the treatment effect between HRD and HRP subgroups (*P*=.80). *Sensitivity analysis*

SFigure 1 summarized the results for PFS by BICR. Data were not available for 5 patients from Study 19 trial^{14, 15, 19}. For patient cohorts with *gBRCAm1*, *gBRCAm2* and *sBRCAm*, results for PFS by BICR were consistent with INV. PFS HRs by BICR did not differ significantly between *gBRCAm1* and *gBRCAm2* (*P*=.23). PFS HRs by BICR were also similar between *gBRCAm1/2* and *sBRCAm* subgroups (*P*=.51).

In *wtBRCA* patients with HRD tumor but without s*BRCAm*, PFS HR by BICR (SFigure1) was also similar to PFS HR by INV (Figure 2). However, there was a difference in PFS HR by BICR for *wtBRCA* patients with HRP tumor as compared with

Cancer

PFS HR by INV. Unlike PFS INV analysis, there was no significant difference in PFS HR by BICR between HRD than HRP subgroups (P=.75).

The treatment effect by BICR was also significantly greater for *BRCAm* (both germline and somatic) than HRD subgroups (P=.004). A similar and consistent finding with BICR as INV was also observed for comparison of *BRCAm* (both germline and somatic) with HRP subgroups (P=.0009).

There was also a borderline significant difference in BICR PFS for patients who only had two versus those with more than two prior platinum chemotherapy lines in the *gBRCAm* cohort (P=.04; SFigure 2).

Publication bias

A funnel plot of the PFS effect size for each trial against the precision showed no asymmetry (data not shown).

Discussion

This meta-analysis demonstrates that maintenance PARPi improves PFS over placebo in PSROC following response to platinum-based chemotherapy in all patients. Our meta-analysis could not identify definitively a subset of patients who may not benefit from PARPi. Patients with *BRCAm* have the greatest PFS benefit, and there is no significant difference in the magnitude of benefit in those with *gBRCAm1*, *gBRCAm2*, and *sBRCAm*. In patients who did not have either a *gBRCAm* or *sBRCAm*, PARPi also significantly reduced the risk of disease progression or death by 59% and 36% in the HRD and HRP subgroups respectively.

Although BRCAm reliably predicts the magnitude of potential PARPi benefit, the absence of BRCAm does not exclude wtBRCA patients with PSROC benefitting from this treatment. There were statistically significant and clinically meaningful PFS improvement in HRD and HRP subgroups with maintenance PARPi. The different HRD assays used in the NOVA, Study 19 and ARIEL3 trials had not reliably identify wtBRCA patients that did not benefit from PARPi. These assays use different platforms, and the number and types of HRD genes analyzed also varied, thus making it difficult to compare results across different assays. Further, with assays designed to measure a putative HRD signature, there needs to be a validated cut-point for classifying patients. The European Society of Medical Oncology has performed a review and recommended that there is currently insufficient evidence to support the use of individual or panels of non-BRCA HRR genes for predicting a PARPi response and further prospective data collection is required²². Ongoing research is also required to harmonize different assays and allow for universal interpretation of test results in order to accurately identify wtBRCA patients that will not benefit from PARPi.

Mutations of HRR genes predict for a similar OS and platinum responsiveness as *gBRCAm* when treated with platinum-based chemotherapy^{19, 23, 24}. There are multiple of these genes, and it has not been specifically clear whether *sBRCAm* predict for similar treatment benefit with PARPi as *gBRCAm*^{25, 26}. This meta-analysis provides robust estimates for quantifying the treatment benefit with data pooled from three RCTs involving more than 100 patients. Although caution still needs to be exercised when interpreting our data, prospective RCTs comparing PARPi versus placebo for *sBRCAm* only is unlikely to be feasible for this relatively rare patient subgroup. Similarly, this

Cancer

meta-analysis remains the only one to report on the relative treatment effect from more than 200 *gBRCAm*² carriers with PSROC, which are much less common than *gBRCAm*¹. Regardless of types of *BRCAm*, germline or somatic, results from this metaanalysis shows that these patients should be treated in an identical manner in routine practice and future trials.

Platinum sensitivity is a strong predictor of the 'BRCAness' phenotype caused by defective homologous recombination due to mechanisms other than gBRCAm1/2^{7, 27}. We observed similar treatment benefit between HRD and *gBRCAm* if the PFI was greater than twelve months (HR 0.34 versus 0.29). In contrast, if the PFI was between six to twelve months, the treatment benefit was inferior for HRD than gBRCAm (HR 0.54 versus 0.25). However, for HRP patients with PFI greater than twelve months, the treatment effect (HR 0.67) was significantly inferior to gBRCAm and HRD subgroups. Therefore, platinum sensitivity is also an imperfect biomarker to predict for response to PARPi, and a robust assay for HRD is still required, even in the context of a PFI greater than twelve months. Interestingly, among the *gBRCAm* only, women who had more than two prior platinum chemotherapy lines had greater PFS benefit as compared to those who only had two chemotherapy lines (HR 0.20 versus 0.31). This finding is hypothesis-generating, as this variable was not a stratification factor in any of the included RCTs, and the difference was of borderline significance (P=.04). Furthermore, prior platinum chemotherapy lines were not predictive in HRD and HRP subgroups.

Strengths and limitations

This study has several strengths. We have conducted a comprehensive review and reported on a number of previously unpublished subgroup data. With a combined

total number of more than 1500 patients from four well-conducted placebo-controlled RCTs, this analysis has greater power to detect differences in subgroups that may be associated with improved PFS benefit. Specifically, having subgroup data available according to HRR gene status allowed us to assess it adequately as predictive biomarkers for benefit with PARPi. Importantly, we were also able to provide a better estimate of the treatment benefit of PARPi in the wtBRCA patient without sBRCAm but had HRD tumors. These patient populations were distinct but several publications^{13, 16} had combined these patient cohorts in the reporting of treatment benefit from PARPi. Our work is further strengthened by the consistencies of the results according to INV and BICR PFS assessments. Our study also has several limitations. We assumed that all PARP inhibitor agents, including olaparib, niraparib, and rucaparib, have equivalent therapeutic efficacy when pooling the data across trials. Data on treatment effect of olaparib remained limited for wtBRCA patients, with only a non-randomized Phase IIIB single-arm study reporting a median PFS of 9.2 months in PSROC treated with olaparib as maintenance treatment²⁸. We acknowledged that the frequency of imaging assessment was different across the RCTs and it could impact on the PFS estimates. We also did not have access to individual patient data to allow missing data be dealt with consistently across trials and to perform multivariable analysis to account for potential confounders. Most importantly, our current analysis is not based on the OS outcome which might be considered to be a more clinically relevant endpoint for this patient population with an incurable cancer. Despite these limitations, this meta-analysis addressed many of the questions important for future research and clinical practice.

Conclusions

Cancer

 In PSROC, maintenance PARPi improves PFS over placebo in women who responded to platinum-based chemotherapy regardless of their *gBRCAm* status. Patients with *sBRCAm* treated with maintenance PARPi have similar magnitude of treatment benefit as those with *gBRCAm*. Although patients with *BRCAm* derive the greatest benefit, the absence of a *BRCAm* or HRD cannot be used to exclude patients from maintenance therapy with a PARPi. As PARPi are being used widely in the first-line setting, there is now greater urgency to identify patients that could potentially be cured with platinum-based chemotherapy followed by maintenance PARPi. Robust tests to identify non-*BRCA* HRR genes and other molecular markers that predict for PARPi benefit is of top priority in future research.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70: 7-30.

2. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 Controls Homology-Directed DNA Repair. Molecular Cell. 1999;4: 511-518.

3. Moynahan ME, Pierce AJ, Jasin M. BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks. Molecular Cell. 2001;7: 263-272.

1 2

60

3 4. Press JZ. De Luca A. Bovd N. et al. Ovarian carcinomas with genetic and epigenetic BRCA1 4 loss have distinct molecular abnormalities. BMC cancer. 2008;8: 17-17. 5 5. The Cancer Genome Atlas Research N, Bell D, Berchuck A, et al. Integrated genomic 6 analyses of ovarian carcinoma. Nature. 2011;474: 609. 7 6. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-Ribose) Polymerase Inhibitors: Recent 8 Advances and Future Development. Journal of Clinical Oncology. 2015;33: 1397-1406. 9 7. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. 10 Nature, 2011:474: 609-615. 11 8. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic 12 ovarian tumours. Nature Genetics. 1995;9: 439-443. 13 9. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic Mutations in BRCA1 and BRCA2 Could 14 Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in 15 Ovarian Cancer. Journal of Clinical Oncology. 2010;28: 3570-3576. 16 10. Foster KA, Harrington P, Kerr J, et al. Somatic and Germline Mutations of the BRCA2 Gene 17 in Sporadic Ovarian Cancer, Cancer Research, 1996:56: 3622-3625. 18 19 11. Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: Response to 20 platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecologic 21 Oncology. 2012;125: 677-682. 22 12. Alsop K, Fereday S, Meldrum C, et al. BRCA Mutation Frequency and Patterns of Treatment 23 Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the 24 Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30: 2654-2663. 25 13. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-26 Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375: 2154-2164. 27 14. Ledermann J, Harter P, Gourley C, et al. Olaparib Maintenance Therapy in Platinum-28 Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366: 1382-1392. 29 15. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with 30 platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of 31 outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15: 852-32 861. 33 16. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent 34 ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, 35 placebo-controlled, phase 3 trial. The Lancet. 2017;390: 1949-1961. 36 37 17. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation 38 39 (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The 40 Lancet Oncology. 2017;18: 1274-1284. 41 18. Poveda A, Floquet A, Ledermann JA, et al. Final overall survival results from 42 SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients with 43 platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38: suppl; 44 abstr 6002. 45 19. Hodgson DR, Dougherty BA, Lai Z, et al. Candidate biomarkers of PARP inhibitor sensitivity 46 in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 2018;119: 1401-1409. 47 20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews 48 and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535. 49 21. Borenstein M, Higgins JP. Meta-analysis and subgroups. Prev Sci. 2013;14: 134-143. 50 22. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing 51 for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals 52 of Oncology. 2020;31: 1606-1622. 53 23. Pennington KP, Walsh T, Harrell MI, et al. Germline and Somatic Mutations in Homologous 54 Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and 55 Peritoneal Carcinomas. Clinical Cancer Research. 2014;20: 764-775. 56 57 58 20 59

1	
2	
3	24 Kondrashova O. Topp M. Nesic K. et al. Methylation of all BRCA1 conjes predicts response
4	to the PARP inhibitor rucanarib in ovarian carcinoma. Nature Communications, 2018:0: 2070
5	to the FARF initiation rucepand in overlan carcinonia. Nature communications. 2010,9, 3970.
6	25. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic
7	BRCA modifications in serous ovarian cancer. Annals of Oncology. 2016;27: 1449-1455.
, 8	26. Dougherty BA, Lai Z, Hodgson DR, et al. Biological and clinical evidence for somatic
0	mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade
9 10	serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8: 43653-43661.
10	27. Konstantinopoulos PA. Spentzos D. Karlan BY. et al. Gene Expression Profile of BRCAness
11	That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With
12	Enithelial Ovarian Cancer, Journal of Clinical Oncology, 2010;28: 3555-3561
13	28 Poyeda A L houroux S. Colombo N. et al. Olanarib maintenance monotherany for non
14	20. Poveda A, Liteureux S, Colombo N, et al. Olapano maintenance monotinerapy for non-
15	germine BRCA 1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR
16	OC) patients (pts): Phase IIIb OPINION Interim analysis. Journal of Clinical Oncology. 2020;38:
17	6057.
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	

Table I: Demographic and treatment characteristics[†]

6 7	рс	oly-ADP ribose polymerase	inhibitor arm		Placebo	
8 9	Germline BRCA	Homologous Recombinant Deficient*	Homologous Recombinant Proficient	Germline BRCA	Homologous Recombinant Deficient*	Homologous Recombinant Proficient
10	N=409* (%)	122	119	201	77	N-121 (70)
Ata<65 years old	(80)	(64)	(52)	(79)	(66)	(47)
Platinum free interval >12	280		135	1/9	71	78
months	(60)	(63)	(60)	(58)	(61)	(64)
Pattial response to platinum	251	109	135	136	63	73
chémotherapy	(54)	(56)	(60)	(53)	(54)	(60)
2 prior lines of platinum	260	119	169	160	77	91
chemotherapy	(55)	(62)	(75)	(63)	(66)	(75)
-19 - 13	379	148	173	204	91	88
Nopprior bevacizumab	(81)	(77)	(77)	(80)	(78)	(73)
27	196			99		
Solution Sol	(42)	NA	NA	(51)	NA	NA
24	53	16	26	43	20	25
Study 19 trial	(11)	(8)	(12)	(22)	(17)	(21)
26	82	106	107	48	52	54
AP7IEL3 trial	(17)	(55)	(48)	(25)	(45)	(45)
28	138	71	92	65	44	42
NOVA trial	(29)	(37)	(41)	(25)	(38)	(35)
- 31	249	16	26			
Oʻlaparib	(53)	(8)	(12)	NA	NA	NA
_33	82	106	107			
Rycaparib	(17)	(55)	(48)	NA	NA	NA
35	138		92			
Nyraparib	(29)	(37)	(41)	NA	NA	NA
37	308			163		
Germline BRCA 1	(66)	NA	NA	(64)	NA	NA
Germline BRCA 2	151	NA	NA	85	NA	NA

Cancer

2							
3		(32)			(33)		
-4						I	
5	tsomatic BRCA r	mutations (N=12	(23) are not included in this T	able 1 Trials contributed to	somatic BRCA mutatio	ons pool are outlined in Figu	ire 2
6	Somalic Di Corri				Somalie Briori matali		
/	[‡] Tho number of r	ationta listad in	this table with complian PP(CA mutations do not match	Eiguro 2 hogougo com	a nationta aithar had both	
8	a remline PPCA 1	allenis listeu in	CINS LADIE WILL GETTIME BAC	of acroling PBCA mutation	rigule z because solli	e patients either had both	
9	germine BRCA		BRCA 2 mutations, or types	or germine BRCA mutation	were unknown.		
10	*Detiente with eer	matic DDCA mus	tation ware avaluated from th		ue recombinent deficie	ADIEL 2 trial defined l	חחו
11	Patients with sor	nalic BRCA mu	lation were excluded from the	is subgroup with homologo		ncy. ARIEL 3 Inal delined F	
12	based on high ge			sing Foundation Medicine	5 NGS assay. NOVA a	and Sludy 19 defined RD i	Jaseu
14	on high LOH, leic		balance, and/or large-scale		a using Mynad Genetic	s mychoice lest.	
15							
16							
17							
18							
19							
20							
21							
22							
23							
24							
25							
26							
27							
20							
30							
31							
32							
33							
34							
35							
36							
37							
38							
39							
40							
41							23
42							20
43							
44 45							
40							

Figure Legends

Figure 1: Flow diagram showing inclusion and exclusion of studies

Figure 2: Relative efficacy analysis according to patient cohorts with germline *BRCA1* mutation, germline *BRCA2*, somatic *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with somatic *BRCA* mutation) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of hazard ratios (HRs) for investigator-assessed progression-free survival for the relative comparison of poly(ADP-ribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for each trial is represented by the square, and the horizontal line crossing the square represents the 95% confidence interval (CI). The diamond represents the pooled overall effect size.

[†]For the NOVA trial, blinded independent central review progression-free survival was the pre-specified primary endpoint of the study, but investigator-assessed progression-free survival result is displayed here.

Figure 3: Relative efficacy analysis according to age, platinum-free interval, response after most recent chemotherapy, number of previous lines of platinum chemotherapy and use of bevacizumab treatment in conjunction with last platinum regimen within patient cohorts with germline *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with somatic *BRCA* mutation) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of pooled hazard ratios (HRs) for investigator-assessed progression-free survival across all trials for the relative comparison of poly(ADP-ribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for

1	
2	
3	each trial is represented by the square, and the horizontal line crossing the square
5	
6	represents the 95% confidence interval (CI).
7	
8	
9	
10	
11	
12	
15	
15	
16	
17	
18	
19	
20	
21	
22	
23	
25	
26	
27	
28	
29	
30 21	
31	
33	
34	
35	
36	
37	
38	
39	
40	
42	
43	
44	
45	
46	
47 48	
49	
50	
51	
52	
53	
54	
56	
57	
58	
59	
60	

Page 26 of 58

Cancer

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive recurrent ovarian cancer: A meta-analysis

Running Title: Predicting benefit with PARP inhibitor

Word count: Abstract, 249 words; Manuscript, 3009 words.

Authors:

Chee Khoon Lee¹, PhD, Michael L Friedlander², PhD, Angelina Tjokrowidjaja¹, MPH, Jonathan A Ledermann³, MD, Robert L Coleman⁴, MD, Mansoor R Mirza⁵, MD, Ursula A. Matulonis⁶, MD, Eric Pujade-Lauraine⁷, PhD, Ralph Bloomfield⁸, MSc, Sandra Goble⁹, MS, Ping Wang¹⁰, PhD, Rosalind M. Glasspool¹¹, PhD, Clare L Scott¹², PhD, on behalf of the Gynecologic Cancer InterGroup Meta-analysis Committee

Affiliations:

¹National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia and the Australia New Zealand Gynaecological Oncology Group

²University of New South Wales Clinical School, Prince of Wales Hospital, Sydney, Australia and the Australia New Zealand Gynaecological Oncology Group

³UCL Cancer Institute and University College London Hospitals, London, UK

⁴Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA ⁵Rigshospitalet–Copenhagen University Hospital, Copenhagen, Denmark and Nordic Society of Gynecological Oncology ⁶Dana–Farber Cancer Institute, Boston, Massachusetts, USA ⁷Université Paris Descartes, AP-HP, Paris, France and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens ⁸Astrazeneca, Cambridge, UK ⁹Clovis Oncology, Boulder, Colorado, USA ¹⁰GlaxoSmithKline, Waltham, Massachusetts, USA ¹¹Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde and University of Glasgow, Glasgow, United Kingdom and Scottish Gynaecological Cancer Trials Group ¹²Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia and the Australia New Zealand Gynaecological Oncology Group **Corresponding Author:**

A/Prof Chee Khoon Lee, MBBS(Hons), FRACP, PhD NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia Email: chee.lee@ctc.usyd.edu.au Ph No: +61295625365; Fax No: +61295651863

Cancer

Funding: There is no specific funding received for this work

Conflict of Interest:

CKL, MF, JAL, MRM, EPL and RMG have received honoraria from AstraZeneca. CKL, MF, JAL, RLC and EPL has provided a consulting or advisory role to AstraZeneca. MF has been involved in a Speaker's bureau for AstraZeneca. CKL, MF, AT, RLC, UAM, EPL have received travel and accommodation funding from AstraZeneca. CKL and RLC have received research funding from AstraZeneca; MF, AT, JAL and MRM have received study grants (to institution) from AstraZeneca. JAL, MRM and RMG have received honoraria from Clovis Oncology. RLC and EPL have provided a consulting or advisory role to Clovis Oncology. JAL has been involved in a Speakers' bureau for Clovis Oncology. JAL and RLC has received travel and accommodation funding from Clovis Oncology. RLC has received research funding from Clovis Oncology, MRM has received study grants (to institution) from Clovis Oncology. MRM and EPL have received honoraria from GlaxoSmithKline. JAL has been involved in a Speakers' bureau for GlaxoSmithKline. RB discloses employment and Stockholder interests with AstraZeneca. SG discloses employment and Stockholder interests with Clovis Oncology. PW discloses employment and Stockholder interests with GlaxoSmithKline. CLS discloses non-financial support and/or other support from AstraZeneca and Clovis Oncology. EPL discloses other relationship with ARCAGY RESEARCH.

Authors contribution:

Conception and design: CKL, MF, CS Collection and assembly of data: CKL, AT, RB, SG, PW Data analysis and interpretation: All authors Manuscript writing: All authors Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

Acknowledgement:

The authors acknowledge provision of unpublished subgroup data from AstraZeneca, Clovis Oncology, and GlaxoSmithKline

Cancer

Precis:

BRCA mutation status could predict for the magnitude of PARP inhibitor benefit in platinum-sensitive recurrent high grade ovarian tumor. However, absence of a BRCA mutation or homologous recombinant deficiency in high grade ovarian tumor could not be used to exclude patients from such therapy.

Abstract

Cancer

Background: We performed a meta-analysis to better quantify benefit of maintenance PARP inhibitor (PARPi) to inform practice in platinum-sensitive recurrent high grade ovarian cancer (PSROC) for these patient subsets: germline *BRCA* mutation (*gBRCAm*), somatic *BRCA* mutation (*sBRCAm*), wild-type *BRCA* and homologous recombinant deficient (HRD), homologous recombinant proficient (HRP), and baseline clinical prognostic characteristics.

Methods: Randomized trials comparing a PARPi versus placebo as maintenance treatment were identified from electronic databases. Treatment estimates for progression-free survival (PFS) were pooled across trials using the inverse variance weighted method.

Results: Four trials included 972 patients receiving a PARPi (olaparib, 31%; niraparib, 35%; or rucaparib, 34%), and 530 patients receiving placebo. For *gBRCAm1* (N=471), HR=0.29 (95% CI 0.23–0.37). For *gBRCAm2* (N=236), HR=0.26 (95% CI 0.17–0.39). For *sBRCAm* (N=123), HR=0.22 (95% CI 0.12–0.41). The treatment effect was similar between *gBRCAm* and *sBRCAm* (P=.48). In wild-type *BRCA* HRD tumors (excluding *sBRCAm*, N=309) HR=0.41 (95% CI 0.31–0.56). In wild-type *BRCA* HRP tumors (N=346), HR=0.64 (95% CI 0.49–0.83). The relative treatment effect was greater for *BRCAm* versus HRD (P=.03), *BRCAm* versus HRP (P<.00001), and HRD versus HRP subgroups (P<.00001) respectively. There was no difference in benefit based on age, response after recent chemotherapy, and prior bevacizumab.

Conclusions: In PSROC, maintenance PARPi improves PFS for all patient subsets. PARPi has similar magnitude of benefit for *sBRCAm* and *gBRCAm*. Although patients

with *BRCAm* derive the greatest benefit, the absence of a *BRCAm* or HRD could not be used to exclude patients from maintenance PARPi therapy.

Keywords: platinum sensitive recurrent ovarian cancer, BRCA mutation, homologous recombination deficiency, polyADP-ribose polymerase inhibitors, meta-analysis

Total number:

(1) text pages: 24

- (2) tables: 1
- (3) figures: 3
- (4) Supporting files for publication: 1

Cancer

Introduction

Cancers of the ovary, fallopian tube and peritoneum remain the most important causes of cancer deaths for women in developed countries¹. At diagnosis, the majority of women have advanced stage disease and approximately 80% will recur following surgery and chemotherapy. Women with platinum-sensitive recurrent ovarian cancer (PSROC), defined as relapse \geq 6 months after the most recent platinum-based chemotherapy, are usually re-treated with further platinum-based agents. There is usually a declining likelihood of response and shorter duration of benefit with each successive line of treatment. Multiple treatment strategies have been extensively investigated in PSROC with the aim of prolonging progression-free survival (PFS) and overall survival (OS). To date the most successful strategies are concomitant chemotherapy and bevacizumab followed by maintenance bevacizumab, and maintenance poly(ADP ribose) polymerase inhibitors (PARPi).

High-grade ovarian tumors accounts for the majority of PSROC and up to 50% are deficient in homologous recombination which is a key pathway involved in DNA damage repair²⁻⁶ and are therefore reliant on more error prone DNA repair pathways such as non-homologous end joining⁷. Various homologous recombination deficiencies have been recognized, including germline mutations of the *BRCA1/2* genes (*gBRCAm 1/2*), somatically acquired *BRCA* mutations (*sBRCAm*), epigenetic *BRCA1* inactivation, or other *BRCA*-independent pathways. To date, *sBRCAm1* were reported in 5–9% of sporadic ovarian tumors, whereas *sBRCAm2* were identified in 3–4% of cases⁸⁻¹⁰. *BRCAm* of either germline^{11, 12} or somatic mutations¹³ occurs more frequently in platinum sensitive than resistant tumors.

PARPi induce synthetic lethality in tumors with homologous recombination deficiency. Multiple randomized controlled trials (RCTs) in PSROC have reported that maintenance PARPi following response to platinum based chemotherapy significantly improves PFS and delays time to subsequent chemotherapy which has changed the standard of care¹³⁻¹⁷ and this treatment is gradually being introduced worldwide. The SOLO2 trial also reported an OS improvement with maintenance olaparib, with 28.3% of *gBRCAm* patients alive at 60 months without need for subsequent treatment, as compared with 12.8% in the placebo arm¹⁸. There is ongoing interest to determine which patient subgroups, beyond those with a *gBRCAm*, will benefit from maintenance PARPi and whether it is possible to use clinico-pathologic factors to select for these patients. This information will be clinically relevant, can help inform the design and interpretation of future trials, and can aid economic analyses.

This paper reports a meta-analysis of four RCTs using published and unpublished data of patient subsets to quantify the relative treatment benefit of maintenance PARPi over placebo in women with PSROC who have responded to platinum-based chemotherapy. We also aimed to determine the variation in treatment benefit based on patient, disease, and past treatment characteristics. This metaanalysis is valuable as individual RCTs were neither designed nor adequately powered to detect differences in treatment effect in these subgroups.

Methods

Study eligibility and identification

We included RCTs of recurrent PSROC with high-grade tumors if they compared PARPi as maintenance therapy versus placebo. Eligible RCTs were identified from

Cancer

MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Search terms used included "*BRCA*", "*BRCA*1", "*BRCA*2", "*BRCA*1 protein", "*BRCA*2 protein", "ovarian neoplasms", "platinum-sensitive", "poly(ADP Ribose) polymerase inhibitors" and "clinical trial". We retrieved relevant articles published between 2005 and 2019 with no language restrictions. Individual trial investigators were also contacted for unpublished subgroup data.

Data collection and analysis

For each RCT, we extracted the trial name, patients' clinico-pathologic characteristics and types of PARPi. Regardless of the primary endpoints of the included RCTs, this meta-analysis assessed treatment benefit based on PFS as assessed by local investigators (INV) as the primary outcome. We performed a sensitivity analysis to determine the consistency of the results based on blinded independent central review (BICR) PFS for all RCTs. BICR PFS was a pre-specified primary endpoint of one included RCT¹³.

We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for PFS based on homologous recombination repair (HRR) deficiency status: *gBRCAm*, *sBRCAm*, wild-type *BRCA* (*wtBRCA*) but homologous recombination deficient (HRD, excluding those with *sBRCAm*) and *wtBRCA* but homologous recombination proficient (HRP). Tumors with oncogenic germline and somatic mutations were classified as *BRCAm* and variants of unknown significance were classified as *wtBRCA*. -If *BRCAm* was detected but the tumor was also tested to be HRP, these patients were classified based on their *BRCAm* status. HRD was defined differently in different RCTs. In one study¹⁶, tumors were classified as HRD if they had high genomic loss of heterozygosity

(LOH) as detected using Foundation Medicine T5 NGS assay (cutoff of 16% or greater). Other studies^{13, 19} defined HRD based on high LOH, telomeric allelic imbalance, and/or large-scale state transitions as detected using Myriad Genetics myChoice test (Genomic Instability Score of 42 or greater).

We also retrieved data on treatment effect for these clinicopathologic subgroups: age (<65 versus \geq 65 years), platinum-free interval (6–12 versus >12 months), response after most recent chemotherapy (complete response versus partial response), number of previous lines of platinum chemotherapy (2 versus >2) and use of bevacizumab treatment in conjunction with last platinum regimen (yes versus no).

Two of the authors (CKL, AT) extracted the data independently, and discrepancies were resolved by a third author (CLS). The risk of bias was assessed based on methods of randomization, allocation concealment, outcome assessments, attrition and reporting of the data. We reported our data based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines²⁰.

Statistical analysis

Pooled PFS HRs and 95% CIs were computed by using the inverse variance weighted method with fixed-effects models. Differences between subgroups were tested using methods described by Borenstein et al²¹. We used the χ^2 Cochran Q test to detect any heterogeneity across trials. We also evaluated publication bias by examining the funnel plot of the effect size for each RCT against the reciprocal of its standard error. The nominal level of significance was set at 5%.

Results

Page 37 of 58

Cancer

We identified four eligible RCTs^{13-17, 19} (Figure 1). Of 1677 patients who were randomly assigned to a PARPi or placebo, we analyzed only patient data from 1502 (89.6%). A total of 175 patients (ARIEL3¹⁶, N=59; Study 19 trial^{14, 15, 19}, N=62; NOVA trial¹³, N=54) were excluded because HRR deficiency status were unknown. All trials recruited patients with high-grade cancers of the ovary, fallopian tube and peritoneum. The majority had predominantly serous histology, whilst only the ARIEL3¹⁶ and SOLO2¹⁷ trials enrolled patients with endometriod and other rare histologies (N=28, 5%, and N=25, 8%, respectively). Table 1 outlines the demographic and treatment characteristics. All included studies were evaluated as low risk for bias (details not shown).

All study sponsors provided unpublished summary subgroup data. All RCTs had a double-blind, placebo-controlled design. The primary endpoint was PFS by BICR for the NOVA trial¹³; PFS by INV was the primary endpoint for other RCTs. The Study 19 trial^{14, 15, 19} was the only trial with a randomized phase II design and the HRR gene status of the tumor was determined retrospectively.

The SOLO2 trial¹⁷ recruited only *gBRCA*m carriers, whereas the remaining RCTs included *gBRCAm*, *sBRCAm* and *wtBRCA* patients. In the ARIEL3 trial¹⁶, *wtBRCA* tumors with HRD was defined based on high genomic LOH. In the Study 19 and NOVA trials, *wtBRCA* tumors with HRD were those with high LOH, telomeric allelic imbalance, and large-scale state transitions.

Benefit of PARP inhibitor in subgroups according to homologous recombination repair deficiency status

Across the trials, 972 patients received a PARPi (olaparib, N=301 [31%];

niraparib, N=336 [35%]; or rucaparib, N=335 [34%]), and 530 patients received placebo.

Among the 471 *gBRCAm1* patients, the pooled PFS HR was 0.29 (95% CI 0.23– 0.37, *P*<.00001; Figure 2). Among the 236 *gBRCAm2* patients, the pooled PFS HR was 0.26 (95% CI 0.17–0.39, *P*<.00001). In the 123 *sBRCA*m patients, the pooled PFS HR was 0.22 (95% CI 0.12–0.41, *P*<.00001).

The pooled PFS HR for both *gBRCAm1* and *gBRCAm2* only was 0.28 (95% CI 0.23–0.35, *P*<.00001). The pooled PFS HR for *gBRCAm1*, *gBRCAm2* and *sBRCAm* was 0.27 (95% CI 0.23–0.34, *P*<.00001).

The relative treatment effect was similar between gBRCAm1 and gBRCAm2 (P=.63). There was also no significant difference in treatment effect between gBRCAm1/2 and sBRCAm (P=.48).

There were 309 *wtBRCA* patients with HRD tumor (excluding s*BRCAm*). The pooled PFS HR was 0.41 (95% CI 0.31–0.56, *P*<.00001). In the 346 *wtBRCA* patients with HRP tumor, the pooled PFS HR was 0.64 (95% CI 0.49–0.83, *P*=.0006). The relative treatment effect was significantly greater for HRD than HRP subgroups (*P*<.00001).

The relative treatment effect was also significantly greater for *BRCAm* (both germline and somatic) than HRD subgroups (HR 0.27 versus 0.41, P=.03). A similar finding was observed for the comparison of *BRCAm* (both germline and somatic) with HRP subgroups (HR 0.27 versus 0.64, *P*<.00001).

Subgroup analyses by clinico-pathologic characteristics

 Cancer

Subgroup outcome data were available for age, response after most recent chemotherapy, number of previous lines of platinum chemotherapy and prior bevacizumab treatment.

In the *gBRCAm* cohort, the pooled HR for patients with only two prior platinum chemotherapy lines (N=420, 58%) was 0.31 (95% CI 0.24–0.41, *P*<.00001). Among the 302 (42%) patients who had more than two prior platinum chemotherapy lines, the pooled HR was 0.20 (95% CI 0.14–0.28, *P*<.00001). The relative treatment effect was borderline significant between these subgroups (*P*=.04; Figure 3). In this *gBRCAm* cohort, the relative treatment benefit of PARPi versus placebo did not vary substantially between the subgroups, based on age, response after most recent chemotherapy, and prior bevacizumab treatment (Figure 3).

In patients with HRD tumors but without s*BRCAm*, PFS HRs did not vary substantially between the subgroups defined by clinico-pathologic characteristics. For patients with HRP tumors, PFS HRs also did not vary substantially in these clinico-pathologic subgroups (Figure 3).

Impact of platinum-free interval on progression-free survival across patient cohorts

Platinum-free interval (PFI) was a stratification factor and defined consistently across all RCTs. A total of 834 patients had PFI greater than twelve months and 545 patients had PFI between six to twelve months. PFS HRs did not vary substantially according to PFI within the *gBRCAm*, HRD, and HRP subgroups (Figure 3).

However, amongst those with PFI greater than twelve months, the pooled PFS HR was 0.29 (95% CI 0.22–0.38, *P*<.00001) in 429 (51%) *gBRCAm* patients. In the 192

(23%) patients with HRD tumor (excluding s*BRCAm*), the pooled PFS HR was 0.34 (95% CI 0.23–0.50, *P*<.00001). There was no significant difference in treatment effect between *gBRCAm* and HRD subgroups (*P*=.56). In contrast, the pooled PFS HR was 0.67 (95% CI 0.48–0.92, *P*=.01) in 213 (26%) patients with HRP tumors. The treatment effect was significantly greater for the comparisons of *gBRCAm* versus HRP (*P*=.0001), and HRD versus HRP subgroups (*P*=.009).

Amongst those with PFI between six to twelve months, 295 (54%) *gBRCAm* patients had a pooled PFS HR of 0.25 (95% CI 0.19–0.34, *P*<.00001). In the 117 (22%) patients with HRD tumors, the pooled PFS HR was 0.54 (95% CI 0.34–0.87, *P*=.01). Among the 133 (24%) patients with HRP tumor, the pooled PFS HR was 0.59 (95% CI 0.38–0.90, *P*=.02). The treatment effect was significantly greater for *gBRCAm* than HRD subgroups (*P*=.007), and for *gBRCAm* than HRP subgroups (*P*=.001). There was no significant difference in the treatment effect between HRD and HRP subgroups (*P*=.80). *Sensitivity analysis*

SFigure 1 summarized the results for PFS by BICR. Data were not available for 5 patients from Study 19 trial^{14, 15, 19}. For patient cohorts with *gBRCAm1*, *gBRCAm2* and *sBRCAm*, results for PFS by BICR were consistent with INV. PFS HRs by BICR did not differ significantly between *gBRCAm1* and *gBRCAm2* (*P*=.23). PFS HRs by BICR were also similar between *gBRCAm1/2* and *sBRCAm* subgroups (*P*=.51).

In *wtBRCA* patients with HRD tumor but without s*BRCAm*, PFS HR by BICR (SFigure1) was also similar to PFS HR by INV (Figure 2). However, there was a difference in PFS HR by BICR for *wtBRCA* patients with HRP tumor as compared with

Cancer

PFS HR by INV. Unlike PFS INV analysis, there was no significant difference in PFS HR by BICR between HRD than HRP subgroups (P=.75).

The treatment effect by BICR was also significantly greater for *BRCAm* (both germline and somatic) than HRD subgroups (P=.004). A similar and consistent finding with BICR as INV was also observed for comparison of *BRCAm* (both germline and somatic) with HRP subgroups (P=.0009).

There was also a borderline significant difference in BICR PFS for patients who only had two versus those with more than two prior platinum chemotherapy lines in the *gBRCAm* cohort (P=.04; SFigure 2).

Publication bias

A funnel plot of the PFS effect size for each trial against the precision showed no asymmetry (data not shown).

Discussion

This meta-analysis demonstrates that maintenance PARPi improves PFS over placebo in PSROC following response to platinum-based chemotherapy in all patients. Our meta-analysis could not identify definitively a subset of patients who may not benefit from PARPi. Patients with *BRCAm* have the greatest PFS benefit, and there is no significant difference in the magnitude of benefit in those with *gBRCAm1*, *gBRCAm2*, and *sBRCAm*. In patients who did not have either a *gBRCAm* or *sBRCAm*, PARPi also significantly reduced the risk of disease progression or death by 59% and 36% in the HRD and HRP subgroups respectively.

Although BRCAm reliably predicts the magnitude of potential PARPi benefit, the absence of BRCAm does not exclude wtBRCA patients with PSROC benefitting from this treatment. There were statistically significant and clinically meaningful PFS improvement in HRD and HRP subgroups with maintenance PARPi. The different HRD assays used in the NOVA, Study 19 and ARIEL3 trials had not reliably identify wtBRCA patients that did not benefit from PARPi. These assays use different platforms, and the number and types of HRD genes analyzed also varied, thus making it difficult to compare results across different assays. Further, with assays designed to measure a putative HRD signature, there needs to be a validated cut-point for classifying patients. The European Society of Medical Oncology has performed a review and recommended that there is currently insufficient evidence to support the use of individual or panels of non-BRCA HRR genes for predicting a PARPi response and further prospective data collection is required²². A consensus on the type of bioinformatics algorithm used to define HRD is required. Ongoing research is also required vital to harmonize these different assays and allow for universal interpretation of test results in order to accurately identify wtBRCA patients that will not benefit from PARPi.

Mutations of HRR genes predict for a similar OS and platinum responsiveness as *gBRCAm* when treated with platinum-based chemotherapy^{19, 23, 24}. There are multiple of these genes, and it has not been specifically clear whether *sBRCAm* predict for similar treatment benefit with PARPi as *gBRCAm*^{25, 26}. This meta-analysis provides robust estimates for quantifying the treatment benefit with data pooled from three RCTs involving more than 100 patients. Although caution still needs to be exercised when interpreting our data, prospective RCTs comparing PARPi versus placebo for *sBRCAm*

Cancer

only is unlikely to be feasible for this relatively rare patient subgroup. Similarly, this meta-analysis remains the only one to report on the relative treatment effect from more than 200 *gBRCAm*² carriers with PSROC, which are much less common than *gBRCAm*¹. Regardless of types of *BRCAm*, germline or somatic, results from this meta-analysis shows that these patients should be treated in an identical manner in routine practice and future trials.

Platinum sensitivity is a strong predictor of the 'BRCAness' phenotype caused by defective homologous recombination due to mechanisms other than gBRCAm1/2^{7, 27}. We observed similar treatment benefit between HRD and *gBRCAm* if the PFI was greater than twelve months (HR 0.34 versus 0.29). In contrast, if the PFI was between six to twelve months, the treatment benefit was inferior for HRD than gBRCAm (HR 0.54 versus 0.25). However, for HRP patients with PFI greater than twelve months, the treatment effect (HR 0.67) was significantly inferior to *gBRCAm* and HRD subgroups. Therefore, platinum sensitivity is also an imperfect biomarker to predict for response to PARPi, and a robust assay for HRD is still required, even in the context of a PFI greater than twelve months. Interestingly, among the *gBRCAm* only, women who had more than two prior platinum chemotherapy lines had greater PFS benefit as compared to those who only had two chemotherapy lines (HR 0.20 versus 0.31). This finding is hypothesis-generating, as this variable was not a stratification factor in any of the included RCTs, and the difference was of borderline significance (P=.04). Furthermore, prior platinum chemotherapy lines were not predictive in HRD and HRP subgroups.

Strengths and limitations

This study has several strengths. We have conducted a comprehensive review and reported on a number of previously unpublished subgroup data. With a combined total number of more than 1500 patients from four well-conducted placebo-controlled RCTs, this analysis has greater power to detect differences in subgroups that may be associated with improved PFS benefit. Specifically, having subgroup data available according to HRR gene status allowed us to assess it adequately as predictive biomarkers for benefit with PARPi. Importantly, we were also able to provide a better estimate of the treatment benefit of PARPi in the wtBRCA patient without sBRCAm but had HRD tumors. These patient populations were distinct but several publications^{13, 16} had combined these patient cohorts in the reporting of treatment benefit from PARPi. Our work is further strengthened -by the consistencies of the results according to INV and BICR PFS assessments. Our study also has several limitations. We assumed that all PARP inhibitor agents, including olaparib, niraparib, and rucaparib, have equivalent therapeutic efficacy when pooling the data across trials. Data on treatment effect of olaparib remained limited for wtBRCA patients, with only a non-randomized Phase IIIB single-arm study reporting a median PFS of 9.2 months in PSROC treated with olaparib as maintenance treatment²⁸ with HRD and HRP tumors. We acknowledged that the frequency of imaging assessment was different across the RCTs and it could impact on the PFS estimates. We also did not have access to individual patient data to allow missing data be dealt with consistently across trials and to perform multivariable analysis to account for potential confounders. Most importantly, our current analysis is not based on the OS outcome which might be considered to be a more clinically relevant endpoint for this patient population with an incurable cancer. Despite these

 Cancer

limitations, this meta-analysis addressed many of the questions important for future research and clinical practice.

Conclusions

In PSROC, maintenance PARPi improves PFS over placebo in women who responded to platinum-based chemotherapy regardless of their *gBRCAm* status. Patients with *sBRCAm* treated with maintenance PARPi have similar magnitude of treatment benefit as those with *gBRCAm*. Although patients with *BRCAm* derive the greatest benefit, the absence of a *BRCAm* or HRD cannot be used to exclude patients from maintenance therapy with a PARPi. As PARPi are being used widely in the first-line setting, there is now greater urgency to identify patients that could potentially be cured with platinum-based chemotherapy followed by maintenance PARPi. Robust tests to identify non-*BRCA* HRR genes and other molecular markers that predict for PARPi benefit is of top priority in future research.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70: 7-30.

2. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 Controls Homology-Directed DNA Repair. Molecular Cell. 1999;4: 511-518.

3. Moynahan ME, Pierce AJ, Jasin M. BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks. Molecular Cell. 2001;7: 263-272.

4. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC cancer. 2008;8: 17-17.

5. The Cancer Genome Atlas Research N, Bell D, Berchuck A, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474: 609.

6. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. Journal of Clinical Oncology. 2015;33: 1397-1406.

7. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474: 609-615.

8. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genetics. 1995;9: 439-443.

9. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer. Journal of Clinical Oncology. 2010;28: 3570-3576.

10. Foster KA, Harrington P, Kerr J, et al. Somatic and Germline Mutations of the BRCA2 Gene in Sporadic Ovarian Cancer. Cancer Research. 1996;56: 3622-3625.

11. Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecologic Oncology. 2012;125: 677-682.

 Alsop K, Fereday S, Meldrum C, et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30: 2654-2663.
 Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375: 2154-2164.
 Ledermann J, Harter P, Gourley C, et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366: 1382-1392.
 Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with

platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15: 852-861.

16. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;390: 1949-1961.

17. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017;18: 1274-1284.

Lancet Oncology. 2017;18: 1274-1284.
 18. Poveda A, Floquet A, Ledermann JA, et al. Final overall survival results from
 SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients with
 platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38: suppl;
 abstr 6002.
 Hodgson DR, Dougherty BA, Lai Z, et al. Candidate biomarkers of PARP inhibitor sensitivity.

19. Hodgson DR, Dougherty BA, Lai Z, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 2018;119: 1401-1409.

 20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.

21. Borenstein M, Higgins JP. Meta-analysis and subgroups. Prev Sci. 2013;14: 134-143.

22. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology. 2020;31: 1606-1622.

23. Pennington KP, Walsh T, Harrell MI, et al. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Clinical Cancer Research. 2014;20: 764-775.

24. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications. 2018;9: 3970. 25. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic

BRCA modifications in serous ovarian cancer. Annals of Oncology. 2016;27: 1449-1455. 26. Dougherty BA, Lai Z, Hodgson DR, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8: 43653-43661.

27. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer. Journal of Clinical Oncology. 2010;28: 3555-3561.

28. Poveda A, Lheureux S, Colombo N, et al. Olaparib maintenance monotherapy for nongermline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis. Journal of Clinical Oncology. 2020;38: 6057.

Table I: Demographic and treatment characteristics[†]

2						
3						
4						
5 Table I: Demo	graphic and tre	atment characteristics	T			
7	рс	oly-ADP ribose polymerase	inhibitor arm		Placebo	
8	Germline	Homologous	Homologous	Germline	Homologous	Homologous
9	BRCA	Recombinant Deficient*	Recombinant Proficient	BRCA	Recombinant Deficient*	Recombinant Proficient
10	N=469 [‡] (%)	N=193 (%)	N=225 (%)	N=255‡(%)	N=116 (%)	N=121 (%)
11	374	123	118	201	77	57
Aĝè≤65 years old	(80)	(64)	(52)	(79)	(66)	(47)
Platinum-free interval >12	280	121	135	149	71	78
months	(60)	(63)	(60)	(58)	(61)	(64)
Pattial response to platinum	251	109	135	136	63	73
chemotherapy	(54)	(56)	(60)	(53)	(54)	(60)
2 prior lines of platinum	260	119	169	160	77	91
chêmotherapy	(55)	(62)	(75)	(63)	(66)	(75)
20	379	148	173	204	91	88
No prior bevacizumab	(81)	(77)	(77)	(80)	(78)	(73)
22	196			99		
SolLO2 trial	(42)	NA	NA	(51)	NA	NA
24	53	16	26	43	20	25
States State	(11)	(8)	(12)	(22)	(17)	(21)
26	82	106	107	48	52	54
A₽?IEL3 trial	(17)	(55)	(48)	(25)	(45)	(45)
28	138	71	92	65	44	42
NOVA trial	(29)	(37)	(41)	(25)	(38)	(35)
30	249	16	26			
Olaparib	(53)	(8)	(12)	NA	NA	NA
32	82	106	107			
Rucaparib	(17)	(55)	(48)	NA	NA	NA
35	138	71	92			
Nijaparib	(29)	(37)	(41)	NA	NA	NA
37	308			163		
Germline BRCA 1	(66)	NA	NA	(64)	NA	NA
Germline BRCA 2	151	NA	NA	85	NA	NA

46

Cancer

1								
2		(00)			(00)			_
_4		(32)			(33)			-
5 6 7	[†] somatic <i>BRCA</i> n	nutations (N=12	3) are not included in this Ta	able 1. Trials contributed to s	omatic BRCA mutations	pool are outlined in Figu	re 2.	
8 9	[‡] The number of p germline <i>BRCA</i> 1	atients listed in and germline <i>E</i>	this table with germline <i>BR</i> BRCA 2 mutations, or types	CA mutations do not match F of germline <i>BRCA</i> mutation v	ïgure 2 because some pa vere unknown.	atients either had both		
10 11 12 13 14 15 16 17 18 19 20 21 21 22 23	[*] Patients with sor based on high ge on high LOH, telo	natic BRCA mut momic loss of he omeric allelic imb	ation were excluded from the eterozygosity as detected us balance, and/or large-scale	nis subgroup with homologou sing Foundation Medicine T5 state transitions as detected	s recombinant deficiency NGS assay. NOVA and a using Myriad Genetics m	. ARIEL 3 trial defined H Study 19 defined HRD b yChoice test.	RD ased	
24 25 26 27 28 29 30								
31 32 33 34 35 36								
37 38 39 40 41								
42 43 44 45							23	

Figure Legends

Figure 1: Flow diagram showing inclusion and exclusion of studies

Figure 2: Relative efficacy analysis according to patient cohorts with germline *BRCA1* mutation, germline *BRCA2*, somatic *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with somatic *BRCA* mutation) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of hazard ratios (HRs) for investigator-assessed progression-free survival for the relative comparison of poly(ADP-ribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for each trial is represented by the square, and the horizontal line crossing the square represents the 95% confidence interval (CI). The diamond represents the pooled overall effect size.

[†]For the NOVA trial, blinded independent central review progression-free survival was the pre-specified primary endpoint of the study, but investigator-assessed progression-free survival result is displayed here.

Figure 3: Relative efficacy analysis according to age, platinum-free interval, response after most recent chemotherapy, number of previous lines of platinum chemotherapy and use of bevacizumab treatment in conjunction with last platinum regimen within patient cohorts with germline *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with somatic *BRCA* mutation) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of pooled hazard ratios (HRs) for investigator-assessed progression-free survival across all trials for the relative comparison of poly(ADP-ribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for

1	
2	
3	each trial is represented by the square, and the horizontal line crossing the square
4	
5	represents the 95% confidence interval (CI).
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
20	
20	
22	
23	
24	
25	
26	
27	
28	
29	
30 21	
37	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
45	
46	
47	
48	
49	
50	
51	
52	
55 54	
55	
56	
57	
58	
59	
60	



1 2									
2 3									
4	Figure 2								
5	•								
6									
7	Subgroup	Weight	Hazard Ratio [95% CI]			PA	RP inhib	oitor (n/N)*	Placebo (n/N)
8	Germline BRCA 1								
9 10	ARIEL3	4.8%	0.24 [0.13, 0.45]				3	4/52	24/29
10	NOVAT	8.3%	0.38 [0.23, 0.61]				5	2/84 [‡]	34/43
11 12	SOLO2	15.3%	0.30 [0.21, 0.43]				/2	/132	51/61
12	Study19	3.7%	0.19 [0.09, 0.39]				170	4/40	22/30
14		32.0%	0.29 [0.23, 0.37]		\bullet		1/2	/308	131/163
15	Heterogeneity: Chi ² =	= 2.89, df = 3	3 (P = 0.41); P = 0%						
16	lest for overall effect	I: Z = 9.81 (F	² < 0.00001)						
17	Germline BRCA 2								
18		2 /0/	0 18 [0 07 0 43]				13	3/30	18/19
19		2.4 /0	0.10[0.07, 0.43]				2	2/50 [‡]	13/18
20	SOLO2	2.0 /0 7 1%	0.36 [0.22, 0.62]				3	1/58	27/35
21	SULU2 Study19	1.170	Not estimable [#]					3/13	11/13
22	Subtotal (95% CI)	11.5%	0.26 [0.17. 0.39]		•		69/	/151	69/85
23	Heterogeneity: Chi ² =	= 4 85 df = 2	P = 0.09 $P = 59%$		•				
24	Test for overall effect	7 = 648 (F	P < 0.00001						
25			10.00001)						
26	Somatic BRCA								
27	ARIEL3	2.8%	0 23 [0 10 0 54]		_		18	8/40	12/16
28	NOVAT	1.8%	0.21 [0.08, 0.59]				18	8/35	10/12
29	Study19	0.8%	0.23 [0.05, 1.12]			+	3	3/10	8/10
30	Subtotal (95% CI)	5.4%	0.22 [0.12, 0.41]		\bullet		39	/85	30/38
31	Heterogeneity: Chi ² =	= 0.03. df = 2	$2 (P = 0.99); I^2 = 0\%$						
32	Test for overall effect	t: Z = 4.89 (F	P < 0.00001)						
33		,	,						
34 25	Wild-type BRCA HR	RD							
22 26	ARIEL3	12.1%	0.44 [0.29, 0.66]				67/	106	45/52
30 27	NOVA [†]	7.7%	0.36 [0.22, 0.60]				48	/71	41/44
20	Study19	2.1%	0.48 [0.18, 1.27]			+	8	/16	11/20
30	Subtotal (95% CI)	21.8%	0.41 [0.31, 0.56]		•		123/	193	97/116
40	Heterogeneity: Chi ² =	= 0.47, df = 2	2 (P = 0.79); l ² = 0%						
40 41	Test for overall effect	t: Z = 5.81 (F	P < 0.00001)						
42									
43	Wild-type BRCA HR	Р					01/	107	50/54
44	ARIEL3	13.8%	0.58 [0.40, 0.85]			-	81/	107	50/54
45	NOVAŤ	11.1%	0.73 [0.48, 1.11]			+	/6	/92	39/42
46	Study19	4.4%	0.60 [0.31, 1.17]			+	175/	26	21/25
47	Subtotal (95% CI)	29.2%	0.64 [0.49, 0.83]		\blacksquare	•	1/5/2	225	110/121
48	Heterogeneity: Chi ² =	= 0.65, df = 2	2 (P = 0.72); l² = 0%						
49	Test for overall effect	t: Z = 3.42 (F	P = 0.0006)						
50	T (1 (050(01)	400.00/	0 00 10 00 0 441		•		F70/	062	427/522
51	Total (95% CI)	100.0%	0.38 [0.33, 0.44]		▼		5/8/	902	437/523
52	Heterogeneity: Chi ² =	= 35.58, df =	15 ($P = 0.002$); $I^2 = 58\%$	0.01	0.1	1	10	100	
53	lest for overall effect	t: ∠ = 13.45	(۲ < 0.00001)	Fav	ors PARP inhibito	r Favors Pla	cebo		
54									
55	* n refers to number of	of progressi	on-free survival events; N re	efers to total	number of evalua	ble patients			
56	# Hazard ratio is not e	estimable di	ue to insufficient number of	events		-			
57	‡ one patient with ho	oth germline	e BRCA 1 and germline BRC	A 2 mutation	s were excluded f	rom analysis			

58 59

Page 55 of 58

Figure 3

roup	PARP inhibitor (n/N)*	Placebo (n/N)*	l ²	Pooled HR	Pinteraction
Age<65 years	194/374	161/201	0%	0.27 (0.22–0.34)	52
Age≥65 years	54/95	45/54	17%	0.32 (0.20–0.52)	.53
Platinum–free interval 6–12 months	123/189	98/106	53%	0.25 (0.19–0.34)	16
Platinum–free interval >12 months	125/280	108/149	0%	0.29 (0.22-0.38)	.46
Complete response	91/218	89/119	0%	0.27 (0.20-0.36)	0.6
Partial response	157/251	117/136	63%	0.27 (0.21–0.35)	.96
2 lines of prior platinum	128/260	122/160	22%	0.31 (0.24–0.41)	
>2 lines of prior platinum	120/207	84/95	56%	0.20 (0.14-0.28)	.04
Prior bevacizumab	55/90	44/51	0%	0.18 (0.11–0.30)	10
No prior bevacizumab	193/379	162/204	75%	0.29 (0.23–0.36)	.10
	70/100	62/77	00/	0.41 (0.28, 0.60)	
Age<65 years	/8/123	03/77	0%	0.41 (0.28-0.60)	.44
Age 265 years	45/70	34/39	0%	0.31 (0.18-0.56)	
Platinum-free Interval 6–12 months	54/72	38/45	0%	0.54 (0.34–0.87)	.14
Platinum–free Interval >12 months	69/121	59/71	0%	0.34 (0.23-0.50)	
	- 51/84	40/53	0%	0.48 (0.30-0.77)	.43
	72/109	57/63	0%	0.37 (0.25-0.55)	
2 lines of prior platinum	71/119	64/77	0%	0.44 (0.29–0.65)	.77
>2 lines of prior platinum		33/39	0%	0.48 (0.28–0.83)	
	29/45	22/25	0%	0.30 (0.13-0.68)	.50
No prior bevacizumab	94/148	/5/91	26%	0.41 (0.29–0.58)	
Age<65 years	. 87/118	54/57	53%	0.46 (0.30–0.70)	
Age≥65 years	88/107	56/64	11%	0.70 (0.47-1.04)	.15
Platinum–free interval 6–12 months		40/43	0%	0.59 (0.38–0.90)	
Platinum–free interval >12 months	97/135	70/78	0%	0.67 (0.48–0.92)	.64
Complete response	69/90	40/48	61%	0.71 (0.45–1.09)	
Partial response	106/135	70/73	0%	0.62 (0.45–0.86)	.65
2 lines of prior platinum	127/169	82/91	0%	0.67 (0.49–0.90)	
>2 lines of prior platinum	48/56	28/30	0%	0.46 (0.22–0.95)	.36
Prior bevacizumab	41/52	31/33	0%	0.67 (0.38–1.17)	
	104/470	70/00	00/		.86
	Age<65 years Age≥65 years Platinum-free interval 6–12 months Platinum-free interval >12 months Complete response Partial response 2 lines of prior platinum Prior bevacizumab No prior bevacizumab Age<65 years Platinum-free interval 6–12 months Platinum-free interval 6–12 months No prior bevacizumab Age<65 years Partial response 2 lines of prior platinum Prior bevacizumab No prior bevacizumab Age<65 years Platinum-free interval 6–12 months Platinum-free interval 6–12 months Complete response Partial response 2 lines of prior platinum	Age<65 years Partial response Patilar lesponse 2 lines of prior platinum -free interval 6–12 months Partial response Age<65 years Age<65 years Patilal response Age<65 years Age<65 years Patilal response 2 lines of prior platinum 	Partial responsePARP inhibitor (n/N)*Placebo (n/N)*Age<65 years	PARP inhibitor (n/N)* Placebo (n/N)* 1² Age<65 years	PARP inhibitor (n/N)* Placebo (n/N)* 1 ² Pooled HR Age<65 years

Cancer

* n refers to number of progression-free survival events; N refers to total number of evaluable patients

Supplementary online content

SFigure 1: Relative efficacy analysis according to patient cohorts with germline *BRCA1* mutation, germline *BRCA2,* somatic *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with *sBRCA*) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of hazard ratios (HRs) for blinded independent central review progression-free survival for the relative comparison of poly(ADP-ribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for each trial is represented by the square, and the horizontal line crossing the square represents the 95% confidence interval (CI). The diamond represents the pooled overall effect size.

SFigure 2: Relative efficacy analysis according to age, platinum-free interval, response after most recent chemotherapy, number of previous lines of platinum chemotherapy and use of bevacizumab treatment in conjunction with last platinum regimen within patient cohorts with germline *BRCA* mutation, wild-type *BRCA* but homologous recombination deficient (excluding those with *sBRCA*) and wild-type *BRCA* but homologous recombination proficient (HRP).

Forest plot of pooled hazard ratios (HRs) for blinded independent central review progression-free survival across all trials for the relative comparison of poly(ADPribose) polymerase (PARP) inhibitors versus placebo in each of the patient cohorts. Hazard ratio for each trial is represented by the square, and the horizontal line crossing the square represents the 95% confidence interval (CI).

3	SFigure 1					
4						
5						
6						
7	Study or Subgroup	Weight	Hazard Ratio 95% CI		PARP inhibitor (n/N)*	Placebo (n/N)*
8	Germline BRCA 1					
9	ARIEL3	3.9%	0.28 [0.13, 0.60]		19/52	14/29
10	NOVA	8.4%	0.39 [0.23, 0.66]	_ _	41/84	27/43
11	SOLO2	13.2%	0.30 [0.20, 0.46]		55/132	40/61
12	Study19	3.9%	0.23 [0.10, 0.50]		11/40	19/29
13	Subtotal (95% CI)	29.4%	0.31 [0.23, 0.41]	◆	126/308	100/162
14	Heterogeneity: Chi ² =	1.41, df = 3	3 (P = 0.70); I² = 0%			
15 16	Test for overall effect:	Z = 8.08 (F	> < 0.00001)			
17	Germline BRCA 2					
18	ARIEL3	3.1%	0 23 [0 10, 0 56]		12/30	15/19
19	NOVA	2.4%	0 12 [0 05 0 33]		16/50	13/18
20	SOL 02	7.8%	0 27 [0 16 0 47]	_	25/58	28/35
21	Study19	1.070	Not estimable [#]		4/13	7/13
22	Subtotal (95% CI)	13.3%	0.23 [0.15, 0.35]	•	57/151	63/85
23	Heterogeneity: $Chi^2 =$	1.81 df = 3	$2 (P = 0.40) \cdot l^2 = 0\%$	•		
24 25	Test for overall effect:	Z = 6.88 (F	P < 0.00001)			
26	Somatic BRCA					
27		27%	0 18 [0 07 0 47]	<u> </u>	9/40	11/16
28		1.6%			15/35	7/12
29	Study10	0.6%	0.27 [0.00, 0.00]		2/10	6/9
30	Subtotal (95% CI)	0.0 % 4 9%	0.20 [0.03, 2.22]		26/85	24/37
31	Hotorogonoity: Chi ² -	0.30 df - 1	D = 0.86 + 12 - 0.0%	-		
32	Telefogeneity. Cfir =	7 - 4.25	2 (1 - 0.00), 1 - 0.00			
33		Z – 4.25 (r	- < 0.0001)			
34	Wild-type BRCA HR	D				
35		10.00/	0 55 10 25 0 901		48/106	32/52
36		0.5%	0.00 [0.00, 0.09]		41/71	38/44
37	NUVA Study10	9.0%	0.30 [0.23, 0.03]		7/16	9/20
38	Subtotal (95% CI)	2.0%	0.00 [0.27, 2.33]		96/193	79/116
39		22.7/0	0.43 [0.33, 0.00]	▼		
40	Telefogeneity: Chr –	2.03, 01 - 2	2(P - 0.30), F - 1%			
41	rest for overall effect.	Z – 4.30 (r	- < 0.0001)			
42	Wild type BPCA HPI	5				
43		4 4 4 0/	0 47 [0 04 0 74]		63/107	46/54
44		14.1%			54/92	35/42
45		11.1%	0.58 [0.36, 0.92]		14/24	20/25
46	Study 19 Subtotal (95% CI)	4.8%	0.45 [0.22, 0.90]		131/223	101/121
47		30.0%		•		
48	Heterogeneity: Chi ² =	0.58, df = 2	2 (P = 0.75); P = 0%			
49	lest for overall effect:	Z = 4.75 (H	J < 0.00001)			
50	Total (05% CI)	100 00/	0 37 [0 32 0 44]		436/960	367/521
51			0.37 [0.32, 0.44]	▼		
52	Heterogeneity: Chi ² =	22.41, dt =	(P = 0.10); P = 33%	0.01 0.1 1	10 100	
53	lest for overall effect:	Z = 12.47	(P < 0.00001)	Favors PARP inhibitor Favors	Placebo	
54						
55 56	* n refers to number o	of progressi	ion-free survival events; N	l refers to total number of evaluable pa	atients	

⁶ # Hazard ratio is not estimable due to insufficient number of events

SFigure 2

Subg	roup	PARP inhibitor (n/N)*	Placebo (n/N)*	l ²	Pooled HR	Pinteractior
	Age<65 years	148/374	127/200	0%	0.28 (0.22–0.36)	
	Age≥65 years	38/95	42/54	0%	0.28 (0.16–0.48)	.99
4	Platinum–free interval 6–12 months	95/189	85/106	29%	0.24 (0.18–0.34)	
RC/	Platinum–free interval >12 months	91/280	84/148	0%	0.26 (0.19–0.37)	.74
Je B	Complete response	68/218	69/119	0%	0.28 (0.20-0.40)	
JI	Partial response	118/251	100/135	0%	0.25 (0.19–0.33)	.61
Gerr	2 lines of prior platinum	94/260	99/159	23%	0.31 (0.22–0.41)	
0	>2 lines of prior platinum	92/207	70/95	35%	0.18 (0.12–0.27)	.04
	Prior bevacizumab	40/90	39/51	0%	0.15 (0.08–0.26)	
	No prior bevacizumab	146/379	130/203	12%	0.29 (0.22–0.37)	.03
ent		(1/122	F1 (77	00/		
μü	Age<65 years	- 64/123	51///	0%	0.51 (0.34–0.77)	.20
l de	Age≥65 years	32/70	28/39	0%	0.31 (0.16-0.59)	
	Platinum–free interval 6–12 months	40/72	34/45	0%	0.50 (0.30-0.83)	.75
	Platinum–free interval >12 months	- 56/121	45/71	37%	0.44 (0.28–0.70)	
a E	Complete response	— 38/84	34/53	0%	0.49 (0.29–0.82)	.80
ר ער	Partial response	- 58/109	45/63	13%	0.45 (0.28–0.71)	
- ch	2 lines of prior platinum	51/119	52/77	0%	0.44 (0.29–0.69)	.41
obo	>2 lines of prior platinum	45/74	27/39	27%	0.60 (0.34–1.06)	
	Prior bevacizumab	> 23/45	17/25	0%	0.55 (0.24–1.24)	.68
Ноп	No prior bevacizumab	73/148	62/91	26%	0.45 (0.31–0.66)	
ent	Age<65 years	68/118	49/57	70%	0.40 (0.25–0.64)	
Ú,	Age>65 years	63/105	52/64	0%	0.52 (0.33–0.82)	.42
bro	Platinum-free interval 6–12 months	58/89	37/43	0%	0.53 (0.33–0.85)	
lon	Platinum-free interval >12 months	73/134	64/78	0%	0.48 (0.34–0.69)	.74
Inat		53/89	35/48	46%	0.61 (0.37–1.00)	
a M	Partial response	78/134	66/73	0%	0.46 (0.32–0.65)	.34
000	2 lines of prior platinum	95/167	76/91	0%	0.53 (0.38–0.74)	
us re	>2 lines of prior platinum	36/56	25/30	39%	0.45 (0.20-1.00)	.71
ogo	Prior bevacizumab	31/52	29/33	0%	0.56 (0.31–1.03)	_
oloc	No prior bevacizumab	100/171	72/88	0%	0.49 (0.35–0.68)	.71
Ĕ			, •••			

* n refers to number of progression-free survival events; N refers to total number of evaluable patients